Royal UNIBREW A/S
15.3.2021 12:33:38 CET | Globenewswire | Press release
COMPANY ANNOUNCEMENT NO 12/2021 – 15 MARCH 2021
On 3 March 2021, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 9/2021 of 3 March 2021. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the Market Abuse Regulation - MAR) and the resulting delegated legislation. The share buy-back program is expected to be realized in the period from 4 March 2021 to 30 June 2021. The total share buy-back in the period will not exceed a market price of DKK 250 million.
The following transactions have been made under the program:
| Number of Shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 5,243 | 629.80 | 3,302,049.17 |
| 8 March 2021 | 9,000 | 648.44 | 5,835,993.30 |
| 9 March 2021 | 3,154 | 651.93 | 2,056,189.43 |
| 10 March 2021 | 2,162 | 674.66 | 1,458,616.00 |
| 11 March 2021 | 3,539 | 667.42 | 2,361,993.72 |
| 12 March 2021 | 3,874 | 664.89 | 2,575,776.11 |
| Accumulated under the program | 26,972 | 652.18 | 17,590,617.73 |
With the transactions stated above Royal Unibrew owns a total of 794,412 shares, corresponding to 1.6% of the share capital. The total amount of shares in the company is 49,350,000, including treasury shares.
For further information on this Announcement:
CFO Lars Vestergaard, tel (+45) 30 93 18 08
www.royalunibrew.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Rapid Nutrition Plc17.11.2026 05:00:00 CET | Press release
Rapid Nutrition Announces SystemLS AI Mobile App to Accelerate International Growth and Create Recurring Subscription Revenue Opportunity
Novartis Pharma AG17.11.2026 03:43:07 CET | Press release
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
AriBio Co., Ltd.17.11.2026 01:51:42 CET | Press release
AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial
AGC Biologics, Inc.17.11.2026 01:00:00 CET | Press release
AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site
NAED Energy Holding Inc17.11.2026 00:13:27 CET | Press release
From Physics to Factory: NAED’s PV-1 Delivers the Tandem Era at 96,000 WPH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
